|
1
|
Xing M: Molecular pathogenesis and
mechanisms of thyroid cancer. Nat Rev Cancer. 13:184–199. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Roberts PJ and Der CJ: Targeting the
Raf-MEK-ERK mitogen-activated protein kinase cascade for the
treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cantwell-Dorris ER, O'Leary JJ and Sheils
OM: BRAFV600E: Implications for carcinogenesis and molecular
therapy. Mol Cancer Ther. 10:385–394. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cancer Genome Atlas Research Network.
Integrated genomic characterization of papillary thyroid carcinoma.
Cell. 159:676–690. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Luke JJ and Hodi FS: Vemurafenib and BRAF
inhibition: A new class of treatment for metastatic melanoma. Clin
Cancer Res. 18:9–14. 2012. View Article : Google Scholar
|
|
6
|
Xing M, Westra WH, Tufano RP, Cohen Y,
Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, et
al: BRAF mutation predicts a poorer clinical prognosis for
papillary thyroid cancer. J Clin Endocrinol Metab. 90:6373–6379.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK,
Lee YJ, Kim KW, Hahn SK, Youn YK, Kim KH, et al: The association of
the BRAF(V600E) mutation with prognostic factors and poor clinical
outcome in papillary thyroid cancer: A meta-analysis. Cancer.
118:1764–1773. 2012. View Article : Google Scholar
|
|
8
|
Xing M, Alzahrani AS, Carson KA, Shong YK,
Kim TY, Viola D, Elisei R, Bendlová B, Yip L, Mian C, et al:
Association between BRAF V600E mutation and recurrence of papillary
thyroid cancer. J Clin Oncol. 33:42–50. 2015. View Article : Google Scholar :
|
|
9
|
Flaherty KT, Puzanov I, Kim KB, Ribas A,
McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, et
al: Inhibition of mutated, activated BRAF in metastatic melanoma. N
Engl J Med. 363:809–819. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim KB, Cabanillas ME, Lazar AJ, Williams
MD, Sanders DL, Ilagan JL, Nolop K, Lee RJ and Sherman SI: Clinical
responses to vemurafenib in patients with metastatic papillary
thyroid cancer harboring BRAF(V600E) mutation. Thyroid.
23:1277–1283. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chook YM and Süel KE: Nuclear import by
karyopherin-βs: Recognition and inhibition. Biochim Biophys Acta.
1813:1593–1606. 2011. View Article : Google Scholar :
|
|
12
|
Stewart M: Molecular mechanism of the
nuclear protein import cycle. Nat Rev Mol Cell Biol. 8:195–208.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
D'Angelo MA and Hetzer MW: Structure,
dynamics and function of nuclear pore complexes. Trends Cell Biol.
18:456–466. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kutay U, Bischoff FR, Kostka S, Kraft R
and Görlich D: Export of importin alpha from the nucleus is
mediated by a specific nuclear transport factor. Cell.
90:1061–1071. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Brinkmann U, Brinkmann E, Gallo M and
Pastan I: Cloning and characterization of a cellular apoptosis
susceptibility gene, the human homologue to the yeast chromosome
segregation gene CSE1. Proc Natl Acad Sci USA. 92:10427–10431.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brinkmann U, Brinkmann E, Gallo M, Scherf
U and Pastan I: Role of CAS, a human homologue to the yeast
chromosome segregation gene CSE1, in toxin and tumor necrosis
factor mediated apoptosis. Biochemistry. 35:6891–6899. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Behrens P, Brinkmann U, Fogt F, Wernert N
and Wellmann A: Implication of the proliferation and apoptosis
associated CSE1L/CAS gene for breast cancer development. Anticancer
Res. 21:2413–2417. 2001.PubMed/NCBI
|
|
18
|
Wellmann A, Flemming P, Behrens P,
Wuppermann K, Lang H, Oldhafer K, Pastan I and Brinkmann U: High
expression of the proliferation and apoptosis associated CSE1L/CAS
gene in hepatitis and liver neoplasms: Correlation with tumor
progression. Int J Mol Med. 7:489–494. 2001.PubMed/NCBI
|
|
19
|
Winkler J, Ori A, Holzer K, Sticht C,
Dauch D, Eiteneuer EM, Pinna F, Geffers R, Ehemann V, Andres-Pons
A, et al: Prosurvival function of the cellular apoptosis
susceptibility/importin-α1 transport cycle is repressed by p53 in
liver cancer. Hepatology. 60:884–895. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Brustmann H: Expression of cellular
apoptosis susceptibility protein in serous ovarian carcinoma: A
clinicopathologic and immunohistochemical study. Gynecol Oncol.
92:268–276. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Peiró G, Diebold J, Baretton GB, Kimmig R
and Löhrs U: Cellular apoptosis susceptibility gene expression in
endometrial carcinoma: Correlation with Bcl-2, Bax, and caspase-3
expression and outcome. Int J Gynecol Pathol. 20:359–367. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bar-Shira A, Pinthus JH, Rozovsky U,
Goldstein M, Sellers WR, Yaron Y, Eshhar Z and Orr-Urtreger A:
Multiple genes in human 20q13 chromosomal region are involved in an
advanced prostate cancer xenograft. Cancer Res. 62:6803–6807.
2002.PubMed/NCBI
|
|
23
|
Wellmann A, Krenacs L, Fest T, Scherf U,
Pastan I, Raffeld M and Brinkmann U: Localization of the cell
proliferation and apoptosis-associated CAS protein in lymphoid
neoplasms. Am J Pathol. 150:25–30. 1997.PubMed/NCBI
|
|
24
|
Böni R, Wellmann A, Man YG, Hofbauer G and
Brinkmann U: Expression of the proliferation and
apoptosis-associated CAS protein in benign and malignant cutaneous
melanocytic lesions. Am J Dermatopathol. 21:125–128. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tai CJ, Hsu CH, Shen SC, Lee WR and Jiang
MC: Cellular apoptosis susceptibility (CSE1L/CAS) protein in cancer
metastasis and chemotherapeutic drug-induced apoptosis. J Exp Clin
Cancer Res. 29:1102010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liao CF, Luo SF, Li LT, Lin CY, Chen YC
and Jiang MC: CSE1L/CAS, the cellular apoptosis susceptibility
protein, enhances invasion and metastasis but not proliferation of
cancer cells. J Exp Clin Cancer Res. 27:152008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jiang MC and Liao CF: CSE1/CAS
overexpression inhibits the tumorigenicity of HT-29 colon cancer
cells. J Exp Clin Cancer Res. 23:325–332. 2004.PubMed/NCBI
|
|
28
|
Yoshiura K, Nishishita T, Nakaoka T and
Yamashita N and Yamashita N: Inhibition of B16 melanoma growth and
metastasis in C57BL mice by vaccination with a syngeneic
endothelial cell line. J Exp Clin Cancer Res. 28:132009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tai CJ, Shen SC, Lee WR, Liao CF, Deng WP,
Chiou HY, Hsieh CI, Tung JN, Chen CS, Chiou JF, et al: Increased
cellular apoptosis susceptibility (CSE1L/CAS) protein expression
promotes protrusion extension and enhances migration of MCF-7
breast cancer cells. Exp Cell Res. 316:2969–2981. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tanaka T, Ohkubo S, Tatsuno I and Prives
C: hCAS/CSE1L associates with chromatin and regulates expression of
select p53 target genes. Cell. 130:638–650. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang J, Lu Z, Wientjes MG and Au JL:
Delivery of siRNA therapeutics: Barriers and carriers. AAPS J.
12:492–503. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Senapedis WT, Baloglu E and Landesman Y:
Clinical translation of nuclear export inhibitors in cancer. Semin
Cancer Biol. 27:74–86. 2014. View Article : Google Scholar : PubMed/NCBI
|
